최소 단어 이상 선택하여야 합니다.
최대 10 단어까지만 선택 가능합니다.
다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
NTIS 바로가기한국임상약학회지 = Korean journal of clinical pharmacy, v.26 no.4, 2016년, pp.341 - 347
김혜린 (삼육대학교 약학대학) , 박재아 (성균관대학교 약학대학) , 신지영 (성균관대학교 약학대학) , 박승후 (성균관대학교 약학대학) , 이의경 (성균관대학교 약학대학)
Background: Liver cirrhosis causes substantial socio-economic burden and is one of the major severe liver diseases in Korea. Nonetheless, there is only a few studies that analyzes disease burden of liver cirrhosis in Korea. Such study must be carried out due to its increasing need from the invention...
* AI 자동 식별 결과로 적합하지 않은 문장이 있을 수 있으니, 이용에 유의하시기 바랍니다.
핵심어 | 질문 | 논문에서 추출한 답변 |
---|---|---|
간경변증의 주 원인은 무엇인가? | 간경변증은 B형간염, C형간염, 알코올 간질환이 주 원인이며, 간경변을 거쳐 간암이 발생한다. 특히 사회경제적으로 활동 능력이 왕성한 40-50대 중년 남성에게서 많이 발생하여3) 직접 의료비용과 함께 생산성 손실비용까지 감안하면, 사회경제적 부담이 상당할 것임을 예상할 수 있다. | |
우리나라 간경변증 환자에서의 주요 원인질환은 무엇이 가장 많은가? | 우리나라에서 간질환, 특히 간경변증의 유병률이 높으며 간경변증은 주요 사망원의 하나로 알려져있다. 우리나라 간경변증 환자에서의 주요 원인질환은 만성B형간염이 64.9%로 가장 많고, 알코올 18. | |
간경변증의 발생은 어떤 연령대에 많이 발생하는가? | 간경변증은 B형간염, C형간염, 알코올 간질환이 주 원인이며, 간경변을 거쳐 간암이 발생한다. 특히 사회경제적으로 활동 능력이 왕성한 40-50대 중년 남성에게서 많이 발생하여3) 직접 의료비용과 함께 생산성 손실비용까지 감안하면, 사회경제적 부담이 상당할 것임을 예상할 수 있다.2) |
The Korean Association for the Study of the Liver and liver cirrhosis clinical research center. Clinical Practice Guideline for Liver Cirrhosis, Update. Seoul: Jin-corp, 2011; 1-83. http://www.kasl.org/bbs/index.html?codeguide&category&gubun&idx&page1&number48&modeview&order&sort&keyfield&key
The Korean Association for the Study of the Liver, White Paper on Liver Diseases in Korea, Seoul: The Korean Association for the Study of the Liver, 2013.
HIRA. Healthcare Bigdata Hub. Available from http://opendata.hira.or.kr/op/opc/olap3thDsInfo.do. Accessed July 14, 2016.
Abergel A, Rotily M, Branchoux S, et al. Chronic hepatitis C: Burden of disease and cost associated with hospitalisations in France in 2012 (The HEPC-LONE study). Clin Res Hepatol Gastroenterol 2016; 40(3): 340-8.
Kieran JA, Norris S, O'Leary A, et al. Hepatitis C in the era of directacting antivirals: real-world costs of untreated chronic hepatitis C; a cross-sectional study. BMC infect Dis 2015;15:471.
Stahmeyer JT, Rossol S, Bert F, et al. Cost of treating hepatitis C in Germany: a retrospective multicenter analysis. Eur J Gastroenterol Hepatol 2014;26(11):1278-85.
Thongsawat S, Piratvisuth T, Pramoolsinsap C, et al. Resource Utilization and Direct Medical Costs of Chronic Hepatitis C in Thailand: A Heavy but Manageable Economic Burden. Clin Res Hepatol Gastroenterol 2014;3:12-8.
Zhang S, Ma Q, Liang S, et al. Annual economic burden of hepatitis B virus-related diseases among hospitalized patients in twelve cities in China. J Viral Hepat 2016;23(3):202-10.
Lu J, Xu A, Wang J, et al. Direct economic burden of hepatitis B virus related diseases: evidence from Shandong, China. BMC Health Serv Res 2013;13:37.
Lim SJ, Jo JH, Kim SH, Status of health insurance system and reform trend in major foreign countries, Seoul: National Health Insurance Service, 2014;1-126.
Lee H, Shin E, Lee C, et al. Medical price levels of OECD countries: A Comparative Study. Research Institute for Healthcare Policy. 2012;11:1-62.
Kwon S, Kim S, Kim T, et al. Comparison of domestic and foreign generic drug prices. National Health Insurance Service?Health Insurance Review and Assessment Service. 2010.
Kim S. Pharmaceutical pricing policies in a global market. OECD health policy studies. 2011.
Lee E, Kim H, Kim B et al. Comparative analysis of drug price level in Korea compared to OECD countries. Sungkyunkwan University? Korean Research-based Pharma Industry Association. 2014.
Kim do Y, Yoon KT, Kim W, et al. Estimation of direct medical cost related to the management of chronic hepatitis C and its complications in South Korea. Medicine 2016;95(30):e3896.
Afdhal N, Reddy KR, Nelson DR, et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med 2014; 370(16):1483-93.
Leleu H, Blachier M, Rosa I. Cost-effectiveness of sofosbuvir in the treatment of patients with hepatitis C. J Viral Hepat 2015; 22(4):376-83.
Linas BP, Barter DM, Morgan JR, et al. The cost-effectiveness of sofosbuvir-based regimens for treatment of hepatitis C virus genotype 2 or 3 infection. Ann Intern Med 2015;162(9):619-29.
Petta S, Cabibbo G, Enea M, et al. Cost-effectiveness of sofosbuvirbased triple therapy for untreated patients with genotype 1 chronic hepatitis C. Hepatology 2014;59(5):1692-705.
Pfeil AM, Reich O, Guerra IM, et al. Cost-effectiveness analysis of sofosbuvir compared to current standard treatment in swiss patients with chronic hepatitis C. PloS one 2015;10(5):e0126984.
San Miguel R, Gimeno-Ballester V, Blazquez A, et al. Cost-effectiveness analysis of sofosbuvir-based regimens for chronic hepatitis C. Gut 2014.
Shepherd J, Jones J, Hartwell D, et al. Interferon alpha (pegylated and non-pegylated) and ribavirin for the treatment of mild chronic hepatitis C: a systematic review and economic evaluation. Health Technol Assess 2007;11(11):1-205, iii.
Siebert U and Sroczynski G. Effectiveness and cost-effectiveness of initial combination therapy with interferon/peginterferon plus ribavirin in patients with chronic hepatitis C in Germany: a health technology assessment commissioned by the German Federal Ministry of Health and Social Security. Int J Technol Assess Health Care 2005;21(1):55-65.
Wright M, Grieve R, Roberts J, et al. Health benefits of antiviral therapy for mild chronic hepatitis C: randomised controlled trial and economic evaluation. Health Technol Assess 2006;10(21):1-113, iii.
The Korean Association for the Study of the Liver. Chronic Hepatitis Clinical Practice Guideline. 2015.
El Khoury AC, Wallace C, Klimack WK, et al. Economic burden of hepatitis C-associated diseases: Europe, Asia Pacific, and the Americas. J Med Econ 2012;15(5):887-96.
Kim Y, Shin S, Park J, et al. Costing methods in Healthcare. National Evidence-based Healthcare Collaborating Agency 2013.
Shon C, Choi HY, Shim JJ, et al. The Economic Burden of Hepatitis A, B, and C in South Korea. Jpn J Infect Dis 2016;69(1): 18-27.
Chen GF, Wei L, Chen J, et al. Will Sofosbuvir/Ledipasvir (Harvoni) Be Cost-Effective and Affordable for Chinese Patients Infected with Hepatitis C Virus? An Economic Analysis Using Real-World Data. PloS one 2016;11(6):e0155934.
Chhatwal J, He T, Hur C, et al. Direct-acting antiviral agents for patients with hepatitis C virus genotype 1 infection are cost saving. Clin Gastroenterol Hepatol 2016.
Virabhak S, Yasui K, Yamazaki K, et al. Cost-effectiveness of directacting antiviral regimen ombitasvir/paritaprevir/ritonavir in treatmentnaive and treatment-experienced patients infected with chronic hepatitis C virus genotype 1b in Japan. J Med Econ 2016;19(12):1144-56.
Lee S, Chung W, Hyun KR. Socioeconomic costs of liver disease in Korea. Korean J Hepatol 2011;17(4):274-91.
*원문 PDF 파일 및 링크정보가 존재하지 않을 경우 KISTI DDS 시스템에서 제공하는 원문복사서비스를 사용할 수 있습니다.
출판사/학술단체 등이 한시적으로 특별한 프로모션 또는 일정기간 경과 후 접근을 허용하여, 출판사/학술단체 등의 사이트에서 이용 가능한 논문
※ AI-Helper는 부적절한 답변을 할 수 있습니다.